On Thursday, Palantir Technologies Inc. ( PLTR ) disclosed a strategic deal with Databricks to merge Palantir’s AI operating system with Databricks’ platform for AI, data warehousing, and data engineering.

The integration of the Databricks Data Intelligence Platform and Palantir Artificial Intelligence Platform (AIP) enables real-time, AI-driven autonomous workflows.

By combining Unity Catalog with Delta Sharing and Palantir’s security features, the partnership provides joint customers with secure, unified access to GenAI, machine learning, and data warehousing.

This collaboration offers a scalable and open data architecture that integrates Palantir's ( PLTR ) Ontology System with Databricks’ powerful processing capabilities.

This partnership reduces the technical and operational challenges of utilizing GenAI, enabling customers to efficiently deploy autonomous workflows into production.

The integration is already driving mission-critical outcomes for customers in both public and private sectors, including the Department of Defense, Department of the Treasury, Department of Health and Human Services, bp and more.

”Over the past four months, we have been working with joint customers who have been amazed at how our two technologies seamlessly integrate into a unified, open, and scalable data architecture through the combination of Unity Catalog through Delta Sharing with the Palantir ( PLTR ) system,” said Rory Patterson, chairman of the board of Databricks Federal.

”Combining Palantir’s fast delivery of business value with Databricks’ leading Data Intelligence Platform will deliver ‘the best of both worlds’ to our joint customers.”

In a separate release, the company penned a deal with Archer Aviation to build the AI foundation for the future of next-generation aviation technologies.

Investors can gain exposure to the stock via Roundhill ETF Trust Roundhill PLTR WeeklyPay ETF and Direxion Daily PLTR Bull 2X Shares ( PLTU ) .

Price Action: PLTR shares are down 0.78% at $83.00 premarket at the last check Thursday.

Read Next:

Palantir’s $4 Million ARPC Estimate ‘Flawed,’ Says ‘Pharma Bro’ Martin Shkreli, But ‘I Wouldn’t Bet Against Them’